Our first release, Ceregram: CASBA, is a cutting-edge software platform that converts simple EEG recordings into detailed patient reports with precise details on patient progression. Ceregram even generates visual illustrations of brain structure—all without the cost or safety concerns of traditional methods. Making complete disease progression monitoring fast, easy, and reliable.
Accepting inquiries at info@vistimlabs.com
Research findings: PET vs Ceregram
Why Ceregram?
Ceregram is the first neurotherapeutic monitoring platform to provide direct biomarkers of disease progression, for a comprehensive view of neurodegeneration. This means personalized treatment with reliable disease tracking. By combining novel non-invasive procedures with machine learning, Ceregram leads the revolution in precision neurology.
Talk to your doctor about Ceregram today to be part of the future of dementia care.
Frequently Asked Questions
Is this qEEG?
No. While qEEG uses frequency analysis to infer arbitrary measures like “concentration” and “attention,” Ceregram operates on an entirely different level. Our patented evoked potential tomography approach sequentially activates neuron columns, one at a time, enabling individual evaluation of the physiological integrity of each column. Combining these insights forms a detailed 3D landscape that correlates strongly with all known dementia biomarkers, something which qEEG cannot offer. Preliminary research suggests this method could be more accurate than PET for diagnosis.
Is this PET?
No, Ceregram does not rely on positron emission; however, Ceregram can help you and your provider understand what your PET might show, so you can make better care decisions. Critically, Ceregram is not radioactive, so it is safe for repeated use.
Is this capable of more than PET?
Yes. While PET is a powerful tool, typically it can only evaluate one endpoint at a time (in rare cases, two). Additionally, it is radioactive and unsafe for routine use. Finally, PET endpoints do not correlate well with other hallmarks of disease: MRI, cognitive assessment results, and more. Ceregram has significant correlations with all biomarkers, protein or otherwise. This is because it is a direct biomarker of progression.
Is this a reliable way to track disease progression?
Yes! Our studies consistently show precise patient triage, with error rates far below natural month-to-month variability. This makes Ceregram a reliable method for tracking disease progression over time.
Where can I get a Ceregram scan?
Ceregram is available to partner dementia treatment facilities. Speak with your doctor to find out if Ceregram is available in their clinic or if they can provide a referral. You can also leave your contact information in our web form on the contact page.
How is this different from an amyloid blood test?
Blood tests are a screening tool, meant to recommend support a decision to use PET; however, they fail for routine monitoring. Ceregram is specifically designed to monitor effects of therapy after diagnosis and during treatment.
Is this FDA Compliant?
Yes, our product is fully FDA compliant. The hardware is FDA approved and the software procedure is registered under 510k exemption.
Disclaimer: Ceregram is intended for cognitive monitoring. Ceregram is not intended to diagnose, treat, cure, or prevent any disease. It is not a standalone diagnostic nor is meant to replace PET, MRI, or other imaging modalities.